Daniel Von Hoff to Lead Cell Therapeutics' Scientific Advisory Board
Complete the form below to unlock access to ALL audio articles.
Cell Therapeutics, Inc. (CTI) has announced that Daniel D. Von Hoff, M.D., F.A.C.P, a leading medical oncologist who has been the lead investigator in the development of important oncology therapeutics, will serve as Chairman of CTI's Scientific Advisory Board.
The purpose of the Scientific Advisory Board will be to assist management in the strategic development of its oncology portfolio and clinical trial design; work with business development on in-licensing and out-licensing opportunities, and assist in the use of translational and personalized approaches to therapeutic targets.
Dr. Von Hoff is currently Physician in Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen), Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute.
Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. An internationally recognized innovator in the development of targeted therapies, he and his colleagues were involved in the development of many approved therapeutic agents that are now used routinely, including paclitaxel, docetaxel, mitoxantrone, fludarabine, clofarabine, alemtuzumab, irinotecan, nelarabine, capecitabine, and vismodegib.
Dr. Von Hoff's laboratory interests and contributions have been in the area of using translational and genomic approaches to individualize therapy for cancer. His laboratory is now concentrating on discovering new targets in pancreatic cancer.
"I am pleased to help build and lead CTI's Scientific Advisory Board, as I am very impressed with the diversity of the CTI portfolio of product candidates and their potential as targeted therapies for patients with unmet needs," said Dr. Von Hoff.
Dr. Hoff continued, "In particular, early indications suggest that CTI's lead pipeline candidate, pacritinib, has promise to be an active JAK2/FLT3 inhibitor for myelofibrosis and other hematology / oncology indications. The Company's vision to discover new treatments that specifically target the underlying disease leading to safer, more effective drugs to treat patients with cancer is spot on. I look forward to contributing to the exciting ongoing work at CTI now and in the future."
Dr. Von Hoff is a past president of the American Association for Cancer Research, a fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.
He also is the 2010 recipient of the David Karnofsky award from the American Society of Clinical Oncology. In addition to being a mentor and teacher for medical students, oncology fellows, graduate students and post-doctoral fellows, Dr. Von Hoff has published 137 book chapters, more than 625 manuscripts and 1,060 abstracts.
He is the founder and editor emeritus of Investigational New Drugs - The Journal of New Anticancer Agents, as well as founding editor-in-chief of Molecular Cancer Therapeutics.
"Dr. Von Hoff is world-renowned for his work in the discovery and development of novel, targeted anti-cancer agents and CTI will benefit significantly from his knowledge and experience," stated James A. Bianco, M.D., President and CEO of CTI. "We are honored to have an individual of his caliber providing strategic advice and leading the formation of our Scientific Advisory Board."
